Online inquiry

IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15731MR)

This product GTTS-WQ15731MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SEMA4D gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001142287.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10507
UniProt ID Q92854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15731MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15258MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ15595MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ1616MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ10756MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ7415MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ4216MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ9156MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ10223MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFB-R593
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW